ArticleNature communications2025
Enhancing kinase-inhibitor activity and selectivity prediction through contrastive learning.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Unified Hierarchical Multiscale Fusion Framework for Drug-Target Affinity Prediction: From Benchmark Performance to Nanomolar Inhibitor Discovery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Results of a Large-Scale Study of the Binding of 50 Type II Inhibitors to 348 Kinases: The Role of Protein Reorganization.Journal of medicinal chemistry · 2026Article
- Results of a large scale study of the binding of 50 type II inhibitors to 348 kinases: The role of protein reorganization.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Developing selective kinase inhibitors is challenging due to the conserved kinase structures and costly kinome profiling experiments, highlighting the need for accurate prediction of kinase-inhibitor affinity and specificity. Here we present MMCLKin, an attention consistency-guided contrastive learning framework that integrates geometric graph and sequence networks with multi-head attention and multimodal, multiscale contrastive learning to accurately and interpretably predict kinase-inhibitor activity and selectivity. MMCLKin outperforms existing methods across two 3D kinase-drug datasets and demonstrates strong generalizability on ten diverse protein-drug and one mutation-aware datasets, and effectively screens on both known and unknown kinase structures. In-depth analysis of attention coefficients reveals that MMCLKin can identify key residues and molecular functional groups critical for kinase-inhibitor binding. Additionally, ADP-Glo assays confirm that five out of 20 MMCLKin-identified compounds inhibit the pathogenic LRRK2 G2019S mutant, with four exhibiting nanomolar-level potency. Collectively, MMCLKin represents a useful tool for discovering potent and selective kinase inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.